These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Valentijn LJ; Koster J; Zwijnenburg DA; Hasselt NE; van Sluis P; Volckmann R; van Noesel MM; George RE; Tytgat GA; Molenaar JJ; Versteeg R Nat Genet; 2015 Dec; 47(12):1411-4. PubMed ID: 26523776 [TBL] [Abstract][Full Text] [Related]
3. Telomere biology including TERT rearrangements in neuroblastoma: a useful indicator for surgical treatments. Kawashima M; Kojima M; Ueda Y; Kurihara S; Hiyama E J Pediatr Surg; 2016 Dec; 51(12):2080-2085. PubMed ID: 27793328 [TBL] [Abstract][Full Text] [Related]
4. Rapid detection of telomerase expression of neuroblastoma in paraffin-embedded tissue: combination of in situ hybridisation and quantitative PCR. Zhao M; Guan Z; Gong L; Liu F; Gu W; Liu L; Jiang K; Cai J; Feng C; Kuick CH; Chang KTE; Wang J; Tang H; Yin M; Mao J Pathology; 2023 Dec; 55(7):958-965. PubMed ID: 37741703 [TBL] [Abstract][Full Text] [Related]
5. The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres. Graham MK; Xu B; Davis C; Meeker AK; Heaphy CM; Yegnasubramanian S; Dyer MA; Zeineldin M Cancer Res Commun; 2024 Jun; 4(6):1533-1547. PubMed ID: 38837897 [TBL] [Abstract][Full Text] [Related]
6. MYCN amplification, TERT rearrangements and ATRX mutations in neuroblastoma: clinicopathological correlates- an Indian perspective. Kerkar AN; Chinnam D; Verma A; Peters NJ; Kakkar N; Trehan A; Singh M; Gupta K Virchows Arch; 2023 Oct; 483(4):477-486. PubMed ID: 37460674 [TBL] [Abstract][Full Text] [Related]
7. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746 [TBL] [Abstract][Full Text] [Related]
8. TERT promotor region rearrangements analyzed in high-risk neuroblastomas by FISH method and whole genome sequencing. Kawashima M; Ueda Y; Kurihara S; Hiyama E Int J Clin Oncol; 2020 Dec; 25(12):2166-2174. PubMed ID: 32894394 [TBL] [Abstract][Full Text] [Related]
9. How Do Telomere Abnormalities Regulate the Biology of Neuroblastoma? Akter J; Kamijo T Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439779 [TBL] [Abstract][Full Text] [Related]
10. Alternative lengthening of telomeres--an enhanced chromosomal instability in aggressive non-MYCN amplified and telomere elongated neuroblastomas. Lundberg G; Sehic D; Länsberg JK; Øra I; Frigyesi A; Castel V; Navarro S; Piqueras M; Martinsson T; Noguera R; Gisselsson D Genes Chromosomes Cancer; 2011 Apr; 50(4):250-62. PubMed ID: 21319260 [TBL] [Abstract][Full Text] [Related]
11. Epigenetic Targeting of Huang M; Zeki J; Sumarsono N; Coles GL; Taylor JS; Danzer E; Bruzoni M; Hazard FK; Lacayo NJ; Sakamoto KM; Dunn JCY; Spunt SL; Chiu B Cancer Res; 2020 Mar; 80(5):1024-1035. PubMed ID: 31900258 [TBL] [Abstract][Full Text] [Related]
12. Recurrent pre-existing and acquired DNA copy number alterations, including focal TERT gains, in neuroblastoma central nervous system metastases. Cobrinik D; Ostrovnaya I; Hassimi M; Tickoo SK; Cheung IY; Cheung NK Genes Chromosomes Cancer; 2013 Dec; 52(12):1150-66. PubMed ID: 24123354 [TBL] [Abstract][Full Text] [Related]
13. MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification. Valent A; Le Roux G; Barrois M; Terrier-Lacombe MJ; Valteau-Couanet D; Léon B; Spengler B; Lenoir G; Bénard J; Bernheim A J Pathol; 2002 Dec; 198(4):495-501. PubMed ID: 12434419 [TBL] [Abstract][Full Text] [Related]
14. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas. Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915 [TBL] [Abstract][Full Text] [Related]
15. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells. Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764 [TBL] [Abstract][Full Text] [Related]
16. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas. Dreidax D; Bannert S; Henrich KO; Schröder C; Bender S; Oakes CC; Lindner S; Schulte JH; Duffy D; Schwarzl T; Saadati M; Ehemann V; Benner A; Pfister S; Fischer M; Westermann F Hum Mol Genet; 2014 Dec; 23(25):6826-37. PubMed ID: 25104850 [TBL] [Abstract][Full Text] [Related]
17. The calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas and its reactivation induces ERK1/2-dependent apoptosis. Casalà C; Gil-Guiñón E; Ordóñez JL; Miguel-Queralt S; Rodríguez E; Galván P; Lavarino C; Munell F; de Alava E; Mora J; de Torres C Carcinogenesis; 2013 Feb; 34(2):268-76. PubMed ID: 23108190 [TBL] [Abstract][Full Text] [Related]
18. Full-length telomerase reverse transcriptase messenger RNA is an independent prognostic factor in neuroblastoma. Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P Am J Pathol; 2003 Mar; 162(3):1019-26. PubMed ID: 12598334 [TBL] [Abstract][Full Text] [Related]
19. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma. Muth D; Ghazaryan S; Eckerle I; Beckett E; Pöhler C; Batzler J; Beisel C; Gogolin S; Fischer M; Henrich KO; Ehemann V; Gillespie P; Schwab M; Westermann F Cancer Res; 2010 May; 70(9):3791-802. PubMed ID: 20424123 [TBL] [Abstract][Full Text] [Related]